Strategic Partnerships Alpha-9 is a clinical stage radiopharmaceutical company with a differentiated capability to target tumor sites while minimizing off target effects. This profile positions it well for co development or licensing deals with oncology focused pharma partners. Potential collaboration value includes upfronts, milestones, royalties and access to a growing pipeline.

CDMO Opportunity As a small organization advancing radiopharmaceutical programs, Alpha-9 will require specialized GMP manufacturing, radiolabel synthesis, quality control, and regulatory support. CDMOs can capture value by providing end to end manufacturing services for clinical programs and potential future commercialization. This could support a faster path to clinic and reduce internal capex.

Platform Licensing Alpha-9 relies on proprietary design technologies to enable bespoke radiopharmaceuticals across multiple oncology targets. This platform could be licensed or co developed with partners seeking to expand radiopharmaceutical portfolios. Structured licensing deals can create recurring revenue through upfront payments and royalties.

Trial Support A robust pipeline implies ongoing and upcoming clinical trials requiring CRO services, imaging partners, patient recruitment networks, and regulatory strategy. Vendors offering radiopharmaceutical specific trial support can win segments through integrated services, enabling faster trial execution and data quality.

Growth Momentum Recent leadership change with the appointment of a new CEO in October 2025, and active investor interest from Lumira Ventures, signal growth and readiness for strategic partnerships. Located in Boston, Alpha-9 benefits from access to a strong biotech ecosystem and academic networks that enable business development opportunities and potential funding partnerships.